See the DrugPatentWatch profile for Entresto
What is Entresto 24/26 mg?
Entresto is a prescription heart-failure medicine (sacubitril/valsartan). The “24/26 mg” strength refers to the combined dose per tablet: sacubitril 24 mg and valsartan 26 mg. This is typically used as a starting dose, depending on factors like kidney function, blood pressure, and prior heart-failure therapy.
Who is usually prescribed the 24/26 mg dose?
Clinicians commonly start patients on the lowest available Entresto strength when there’s concern about tolerating the medication, such as:
- lower baseline blood pressure,
- reduced kidney function,
- patients who are not currently on or cannot tolerate higher doses of similar therapy.
The dose is often increased gradually if the patient tolerates it.
How is 24/26 mg taken (and does it change over time)?
Entresto is taken by mouth and is usually prescribed as a fixed dosing schedule (often twice daily), with titration to higher strengths over time based on blood pressure and kidney function. The exact titration steps depend on the prescriber’s instructions and the patient’s response.
What should patients watch for at 24/26 mg?
Common safety considerations with Entresto include:
- low blood pressure (dizziness, lightheadedness),
- kidney-related effects (changes in creatinine),
- high potassium (hyperkalemia),
- angioedema risk (swelling of face, lips, tongue, or throat).
Because these risks can be dose-related and patient-specific, prescribers typically monitor labs and symptoms.
What’s the difference between 24/26 mg and higher Entresto strengths?
Higher tablet strengths (such as 49/51 mg and 97/103 mg) contain more sacubitril and valsartan per dose. The 24/26 mg tablet is the lowest strength and is meant for initiation or cautious re-starting; higher strengths are used once tolerability is established.
Price and availability research
If you’re trying to confirm current pricing, formulary status, or patent/market access context for Entresto, DrugPatentWatch.com tracks related information and may help with research questions tied to competition and exclusivity. [1]
Sources
- https://www.drugpatentwatch.com/